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(no CSF leak; CSF leak; death). The effectiveness outcome measure was a utility index 
given to each state based on the hypothesis that utility was 1 for “no CSF leak”; 0.5 
for “CSF leak” and 0 for “death”. RESULTS: When hydrogel was used, the probabili-
ties were for no CSF leak 1.000 at T0; 0.936 at T1 and 0.876 at T2; for CSF leak 
0.000 at T0; 0.043 at T1 and 0.082 at T2; and for death 0.000 at T0; 0.021 at T1 
and 0.042 at T2. When no hydrogel was used, the probabilities were for no CSF leak 
0.060 at T0; 0.876 at T1; 0.767 at T2; for CSF leak 0.940 at T0; 0.103 at T1 and 
0.191 at T2; and for death 0.000 at T0; 0.021 at T1 and 0.042 at T2. The cost-
 effectiveness ratio was a4,720.20 at T0; a5,174.29 at T1 and a5,645.06 at T2 
when hydrogel was used and it was a27,693.48 at T0; a14,251.71 at T1 and 
a12,638.00 at T2 when hydrogel was not used. The ICER, which represents 
the additional cost necessary to gain one additional utility unit, was a9857.12. 
 CONCLUSIONS: The strategy with hydrogel was more cost-effective than the 
strategy without hydrogel.
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OBJECTIVES: Sugammadex (SGX) is a modiﬁed G-cyclodextrin that has been recently 
marketed in Spain for the reversal of neuromuscular block induced by rocuronium 
(ROC) and vecuronium. The objective of this study was to evaluate the cost-
 effectiveness of sugammadex in the management of patients with unanticipated 
 difﬁcult intubation and patients needing rapid sequence intubation from the Spanish 
National Health System perspective. METHODS: Two decision-analytic models were 
developed to assess the average per patient treatment costs (a2009), life-years gained, 
and incremental cost per life-year gained of ROC  SGX vs. succinylcholine in patients 
needing rapid sequence intubation and ROC SGX vs. all other neuromuscular block-
ing agents in the management of the unanticipated difﬁcult intubation patients. The 
models simulate the probability of not being able to intubate, the probability of 
experiencing an adverse effect, and the direct costs produced by each treatment alter-
native. Clinical data was obtained from the SmPC of each drug and form secondary 
sources. Costs were obtained for Soikos database. All data was validated by a focus 
group in order to adapt the model to the Spanish clinical practice. RESULTS: In the 
management of unanticipated difﬁcult intubation patients, ROCSGX is associated 
with higher life years gained and less costs than the intubation with atracurium or 
cisatracurium and with a mean cost per life year gained (LYG) of a11,077 vs. succi-
nylcholine based regimens. In the rapid sequence intubation model, ROCSGX is 
associated with mean expected costs of a58.11 and mean expected life years of 20.38, 
and succinylcholine with a57.89 and 20,37, meaning a cost per LYG of ROCSGX 
vs succinylcholine of a3106. CONCLUSIONS: Under the established assumptions, 
sugammadex would be a cost-effective alternative for the reversal of patients with 
unanticipated difﬁcult intubation or for the management of patients undergoing rapid 
sequence intubation.
PND20
REVERSAL OF NEUROMUSCULAR BLOCKADE WITH SUGAMMADEX—
COST-EFFECTIVENESS ANALYSIS
Calado F1, Félix J2, Rabiais S1, Vilela H3
1Exigo Consultores, Alhos Vedros, Portugal, 2Exigo Consultores, Alhos Vedros, Lisbon, 
Portugal, 3Hospital Fernando Fonseca, Amadora, Portugal
OBJECTIVES: To assess the cost-effectiveness of sugammadex for reversal of neuro-
muscular blockade (NMB) in Portuguese hospitals, using a clinical decision model. 
METHODS: We compared sugammadex 2.0 mg/kg with neostigmine 50 Mg/kg plus 
atropine 0.375 mg. Clinical efﬁcacy and safety data were obtained from both pub-
lished literature and phase III randomized clinical trial supporting the need for routine 
reversal of rocuronium or vecuronium NMB. Clinical events considered were drug 
adverse reactions and post-operative residual curarization. Risk of death within hos-
pitalization, duration and cost of hospitalization were estimated from hospitalizations 
in Portuguese public hospitals during 2007, with at least one surgical procedure. Only 
direct costs were considered (drugs, medical visits, side effect treatments and monitor-
ing). Effectiveness was measured in life years (LY). Premature death accounted to LY 
as the loss of remaining lifespan. Monte Carlo simulations were used to assess second-
order uncertainty. RESULTS: NMB reversal with sugammadex was estimated to result 
in a per patient gain of 2.25 LY (95%CI [1.78; 2.74]) and a decrease of a1509 (95%CI 
[-6,148; 738]) on total cost when compared to the neostigmine-atropine alternative, 
being on average a dominant strategy. Probabilistic sensitivity analysis revealed 82.6% 
probability of sugammadex dominance and 100% of being cost-effective at a thresh-
old of a1000. CONCLUSIONS: Neuromuscular blockade reversal with sugammadex 
may be considered a cost-effective strategy in comparison to neostigmine-atropine.
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OBJECTIVES: We examined whether rasagiline, a once-daily irreversible monoamine 
oxidase type-B inhibitor indicated for treatment of early Parkinson’s disease, is a 
cost-effective ﬁrst-line treatment strategy when compared with ropinirole XL, prami-
pexole, generic ropinirole, and ﬁrst-line levodopa. METHODS: We developed a 5-year 
Markov model to examine the cost-effectiveness of initiating early treatment of PD 
with rasagiline from a United States payer perspective. Comparator strategies included 
initiating therapy with ropinirole XL, pramipexole, generic ropinirole, or levodopa. 
Rasagiline was followed by either a dopamine agonist (DA) or levodopa. DA was 
followed by levodopa. Patients on a DA or levodopa could develop dyskinesias. Health 
state transitions occurred every 6 months. Transition probabilities were from clinical 
trial data. Drug costs, medical costs and utility weights were from published sources. 
One-way and probabilistic sensitivity analyses were performed. Costs and outcomes 
were discounted at 3% per year. RESULTS: Over 5 years, ﬁrst-line treatment with 
rasagiline was cost saving and more effective when compared to branded DAs and 
levodopa. Rasagiline was cost-effective versus generic ropinirole at $1,838 per quality-
adjusted life-year (QALY): incremental costs $239 and incremental QALYs 0.13. 
After ﬁve years compared to a DA, 23% and 50% fewer patients who initiated treat-
ment with rasagiline were taking levodopa and experiencing dyskinesias respectively. 
Compared to ﬁrst-line levodopa, 52% and 69% fewer patients starting rasagiline were 
taking levodopa and experiencing dyskinesias respectively. CONCLUSIONS: Initiat-
ing early Parkinson’s disease therapy with rasagiline delayed treatment with levodopa, 
reduced dyskinesias, and appears to be cost-savings or cost-effective when compared 
to initiating therapy with other ﬁrst-line therapies.
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OBJECTIVES: The societal costs of caring for patients with Alzheimer’s disease 
(AD) are substantial. In light of increasing AD prevalence, there is a need for efﬁcient 
allocation of available resources and despite few therapeutic alternatives the cost-
effectiveness of treatment with cholinesterase inhibitors has been the issue of much 
debate. The objective of this study was to use recently collected data on costs and 
utilities at different stages of AD to estimate the cost-effectiveness of donepezil com-
pared to placebo in mild-to-moderate AD in Sweden. METHODS: A twelve state 
Markov-model was developed, incorporating cognitive function (mild/moderate/
severe), ADL-dependency (independent/dependent) and care setting (home/institution). 
Data on efﬁcacy and disease progression were based on a 1-year clinical trial in 
Northern Europe and costs and utilities were based on a recently conducted cost-of-
illness study in Sweden. The cohort was simulated over ﬁve years in 6-month cycles. 
Patients were assumed to receive treatment during one year, and after that disease 
progression rates were assumed to be identical in the donepezil and the placebo group. 
RESULTS: In base case scenario, the treatment cost of donepezil (11,023 SEK) was 
offset by lower other costs of care (17,618 SEK), resulting in an overall cost-saving 
of 6595 SEK per patient compared to placebo. Donepezil treatment also delayed pro-
gression into severe AD, ADL-dependence and institutionalization and led to a gain 
of 0.056 quality-adjusted life-years (QALY). Sensitivity analyses were carried to 
analyze the impact of extending the period under which treatment costs were incurred 
and by altering the baseline characteristics. Donepezil was cost-saving in most of these 
alternative scenarios and cost-effective in all of them. CONCLUSIONS: Using new 
data on costs and utilities in AD, donepezil treatment in mild-to-moderate AD is 
cost-saving compared to placebo. Treatment delays progression into severe AD, ADL-
dependence and institutionalization and thereby leads to QALY gains.
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OBJECTIVES: Health economic evaluation on the relative value of lamotrigine (LTG) 
and levetiracetame (LEV) in the initial monotherapy of epilepsy METHODS: Paral-
leling an open label, prospective, randomised, multicenter trial including 409 epilepsy 
patients, a health economic evaluation of 81 participants aged q18 years was con-
ducted. Data collection was done by the CRF of the clinical trial and in a series of 
three telephone interviews (baseline and two follow up calls, 3 and 6 months after 
baseline, respectively). The telephone interviews comprised sociodemographics, as well 
as instruments for the evaluation of health-related quality of life, depression and 
resource use). RESULTS: Eighty-one epilepsy patients were included in the economic 
evaluation. Thirty-eight (46.9%) patients were female: 21 (53.8%) in the LTG arm 
and 17 (40.5%) in the LEV arm. The mean duration of the disease was 2.0 o 3.9 
years (LTG) and 2.2 o 6.1 years (LEV). Over the survey period, there was no signiﬁcant 
difference concerning the number of ambulatory consultations (LTG 28 vs. LEV 26) 
or stationary hospital care (LTG 33 vs. LEV 38), though there was a trend for more 
